share_log

Goldman Sachs Initiates Coverage On Krystal Biotech With Buy Rating, Announces Price Target of $160

Goldman Sachs Initiates Coverage On Krystal Biotech With Buy Rating, Announces Price Target of $160

高盛以买入评级启动对Krystal Biotech的报道,宣布目标股价为160美元
Benzinga ·  2023/11/20 05:01

Goldman Sachs analyst Andrea Tan initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Buy rating and announces Price Target of $160.

高盛分析师安德里亚·谭以买入评级开始报道克里斯塔尔生物科技(纳斯达克股票代码:KRYS),并宣布目标股价为160美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发